By Meg Tirrell, Adam Cancryn, CNN (CNN) — The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology that’s been a target of some Trump administration health offi…
Local News 8's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Names this update
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says
Headline from Local News 8 ·
Newest
US FDA declines Moderna flu vaccine review amid vaccine guidance rollback
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot. The
It’s rare that FDA refuses to file an application, particularly for a new vaccine, which requires companies and FDA staff to engage in months or years of discussions.
The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA technology. The company announced the news on Tuesday. The FDA
WASHINGTON (AP) — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA
FDA refuses Moderna mRNA flu vaccine application, citing inadequate study design that could delay stronger protection shot, as Stéphane Bancel says decision contradicts prior FDA guidance.
By Meg Tirrell, Adam Cancryn, CNN (CNN) — The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology that’s been a target of some Trump administration health offi…
The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk
